St. Louis biotech startup Arch Oncology raised $105 million in a funding round.
The round was led by Eventide Asset Management, Cowen Healthcare Investments and 3x5 Partners.
Arch Oncology is developing biologic therapies to treat patients with tumors and hematologic malignancies.
Read more from the St. Louis Business Journal.
Dynamic Strides Therapy to address growing demand with future expansion.